Nomura Holdings Inc. Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Nomura Holdings Inc. lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 57.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,500 shares of the biotechnology company’s stock after selling 6,000 shares during the period. Nomura Holdings Inc.’s holdings in Blueprint Medicines were worth $415,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Compass Wealth Management LLC acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $69,000. Van ECK Associates Corp increased its position in shares of Blueprint Medicines by 28.4% in the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 193 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $95,000. Calton & Associates Inc. acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $224,000. Finally, Intrust Bank NA acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $247,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BPMC shares. SVB Leerink raised shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and increased their price objective for the stock from $50.00 to $97.00 in a research report on Monday, May 6th. HC Wainwright raised their price target on shares of Blueprint Medicines from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, May 3rd. The Goldman Sachs Group raised their price target on shares of Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a report on Monday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a report on Thursday, May 2nd. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Friday, June 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average price target of $108.00.

Insider Transactions at Blueprint Medicines

In other news, insider Percy H. Carter sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $105.13, for a total value of $420,520.00. Following the transaction, the insider now directly owns 41,895 shares in the company, valued at approximately $4,404,421.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Percy H. Carter sold 4,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $105.13, for a total value of $420,520.00. Following the sale, the insider now directly owns 41,895 shares in the company, valued at approximately $4,404,421.35. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Michael Landsittel sold 10,000 shares of Blueprint Medicines stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the completion of the sale, the chief financial officer now owns 47,286 shares in the company, valued at $4,965,030. The disclosure for this sale can be found here. In the last three months, insiders have sold 59,864 shares of company stock worth $6,272,263. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Trading Down 0.9 %

Blueprint Medicines stock opened at $104.23 on Friday. The firm’s 50-day moving average is $101.33 and its 200-day moving average is $91.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $111.02. The company has a market cap of $6.53 billion, a P/E ratio of -21.67 and a beta of 0.70.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.32. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The company had revenue of $96.12 million for the quarter, compared to the consensus estimate of $82.58 million. On average, equities analysts expect that Blueprint Medicines Co. will post -5.15 earnings per share for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.